entity

BIOMARKER

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about BIOMARKER: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

20Connections
30Hypotheses
0Analyses
11Outgoing
9Incoming
8Experiments
0Debates

No AI portrait yet

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Vestibular Function Testing in Corticobasal Syndrome

diagnostic · 3633 words

Outgoing (11)

TargetRelationTypeStr
h-cef0dd34targeted_byhypothesis1.00
h-var-3049fa9ae4targeted_byhypothesis1.00
Prostate Cancerbiomarker_fordisease0.95
Agingbiomarker_forprocess0.95
Thyroid Cancerbiomarker_fordisease0.95

Incoming (9)

SourceRelationTypeStr
h-cef0dd34targetshypothesis1.00
h-var-3049fa9ae4targetshypothesis1.00
biomarkers-biomarker-classification-cbsdescribeswiki0.90
biomarkers-chitotriosidasedescribeswiki0.90
biomarkers-fabp3-fatty-acid-binding-protein-3describeswiki0.90

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Ketone Utilization Index as Metabolic Flexibility Biomarker 0.829 translational neuroscience Which metabolic biomarkers can distingui
CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Wind 0.801 neuroimmunology TREM2 in Alzheimer's Disease: Mechanisms
Integrated Biomarker Panel for Therapeutic Window Identifica 0.784 neurodegeneration What are the precise temporal dynamics o
sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy 0.757 neurodegeneration View
p16^INK4a-CCF Axis as Senolytic Timing Biomarker 0.755 molecular biology What is the optimal therapeutic window t
Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in 0.735 Alzheimer's disease TREM2 agonism vs antagonism in DAM micro
TDP-43 condensation thermodynamics as a therapeutic target a 0.724 neuroscience How can subcellular compartmentalization
Creatine Kinase System Capacity as Neural Energy Reserve Bio 0.707 translational neuroscience Which metabolic biomarkers can distingui
CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of A 0.705 - What blood-brain barrier permeability ch
Pericyte-targeted senolysis or senomorphic therapy will bene 0.700 neurodegeneration Does pericyte senescence drive BBB break
Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification 0.677 translational neuroscience Which metabolic biomarkers can distingui
Pericyte-First Sequential Biomarker Cascade — Soluble PDGFR- 0.662 - Blood-brain barrier permeability changes
Retromer-dependent retrograde endosomal signaling compartmen 0.645 neuroscience How can subcellular compartmentalization
TREM2-Driven Senescence Biomarker Index for Predicting Neuro 0.642 neurodegeneration Gene expression changes in aging mouse b
APOE ε4-driven microglial lipid handling as proximal driver 0.626 neurodegeneration Non-Neuronal Transcriptional Changes Pre
CSF Biomarker-Guided ABCA7 Therapeutic Dosing 0.619 neurodegeneration Why does the V1613M variant reduce amylo
Cell-state stratification is required to resolve Non-Neurona 0.612 neurodegeneration Non-Neuronal Transcriptional Changes Pre
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Non-Neuronal Transcriptional Changes Pre
Neurovascular Permeability Score (NVPS): Composite Plasma + 0.600 - Blood-brain barrier permeability changes
GFAP Perivascular Redistribution (End-Feet Retraction) as Tr 0.594 - Blood-brain barrier permeability changes
Dynamic Microglial Phenotype Switching Biomarker Panel for N 0.577 neurodegeneration What amyloid threshold level is required
A genetically encoded reporter for axonal mitochondrial prot 0.565 neuroscience How can subcellular compartmentalization
Multi-Biomarker Composite Index Surpassing Amyloid PET for T 0.559 neurodegeneration Multi-modal Biomarker Panel Design for E
Real-time closed-loop transcranial focused ultrasound target 0.542 Alzheimer's disease Circuit-level neural dynamics in neurode
Lactate/Pyruvate Ratio Dynamics in CSF as a Neuroinflammatio 0.532 translational neuroscience Which metabolic biomarkers can distingui
Basal cGAS Derepression as Stratification Biomarker 0.520 neurodegeneration What determines the specificity of TDP-4
High baseline tau and ISR activation may lower the effective 0.510 neurodegeneration -
Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neur 0.503 translational neuroscience Which metabolic biomarkers can distingui
Disease-Elevated CHI3L1/CHIT1 Chitinases Are Biomarkers and 0.502 ALS What are the mechanisms by which microgl
Sonic hedgehog pathway compartmentalization as quantitative 0.485 neuroscience How can subcellular compartmentalization

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (8)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
AECII-specific HMGCS2 overexpression in mouse pulmonary fibrosis validation idiopathic pulmonary fibrosis 0.950 0.00 C57BL/6 mice with AECII-specif proposed N/A
Ketogenic diet fat threshold analysis in wild-type mice validation metabolic disease 0.900 0.00 C57BL/6J wild-type mice proposed N/A
HMGCS2 gain-of-function in AECII lipid metabolism regulation exploratory idiopathic pulmonary fibrosis 0.900 0.00 human AECIIs proposed N/A
Ketogenic diet efficacy in diet-induced obese mice validation obesity, metabolic disease 0.900 0.00 C57BL/6J diet-induced obese mi proposed N/A
Autophagy receptor identification for stress granule elimination exploratory neurodegenerative diseases 0.900 0.00 cultured cells under arsenite proposed N/A
Chi3l1 deletion effects on baseline glial activation in mice validation baseline neuroinflammation 0.900 0.00 Chi3l1 knockout mice proposed N/A
Microarray and single-cell RNA analysis of lipid metabolism genes exploratory idiopathic pulmonary fibrosis 0.850 0.00 human patients, mouse models proposed N/A
CHI3L1 variant association with AD progression in human patients exploratory Alzheimer's disease 0.850 0.00 human patients proposed N/A

Related Papers (17)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] Yu CH, Davidson S, Harapas CR, Hilton JB Cell 2020 2
Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis [PMID:40771159] Padilla CM, Lafyatis R, Gibson KF, Morse Arthritis Care Res (Hoboken) 2026 0
Obstructive sleep apnea, biomarker profiles, and clinical progression in Parkins [PMID:41499940] Zhu S, An D, Liu X Sleep Med 2026 0
SuPAR levels are increased in sera of euthymic patients with bipolar disorder an [PMID:41605346] Kök Kendirlioğlu B, Çörekli Kaymakçı E, J Affect Disord 2026 0
Chitinase-like Proteins YKL-40 and YKL-39 in Colorectal Cancer. [PMID:41677627] Ivanova T, Kazakova M, Dikov D, Dzhambov Cells 2026 0
Correction: CHI3L1: An Emerging Player in Neuroinflammation and Neurodegeneratio [PMID:41699333] Mushtaq Umar; Seh Bilal Ahmad; Khanday F Molecular Neurobiology 2026 0
UNC93B1 promotes pancreatic cancer progression through modulation of cGAS-STING [PMID:41716413] Yang H, Li Y, Su J, Zhang H, Zhu W et al Front Immunol 2026 0
Association of Alzheimer's disease progression with YKL40 levels in peripheral b [PMID:41725729] Yang Q, Wang R, Pei J, Fu Q, Zhan Y et a Front Neurol 2026 0
Constitutive neuronal expression and disease-associated upregulation of chitinas [PMID:41762671] Gaur N, Angerer C, Gunes ZI, Ancau M, Wa Brain 2026 0
Plasma CHI3L1 as a marker of cognitive and structural brain changes in radiologi [PMID:41953284] Schneider R, Brand-Arzamendi K, Lim TR, BMJ Neurol Open 2026 0
Neurodegeneration and demyelination in multiple sclerosis. [PMID:38889714] Garton T, Gadani SP, Gill AJ, Calabresi Neuron 2024 0
STING orchestrates the neuronal inflammatory stress response in multiple scleros [PMID:38878778] Woo MS, Mayer C, Binkle-Ladisch L, Sonne Cell 2024 0
Air pollution, glymphatic impairment, and Alzheimer's disease. [PMID:37777345] Hussain R, Graham U, Elder A, Nedergaard Trends in neurosciences 2023 0
Roles of neuropathology-associated reactive astrocytes: a systematic review. [PMID:36915214] Lawrence JM, Schardien K, Wigdahl B, Non Acta neuropathologica communic 2023 0
Gasdermin-E mediates mitochondrial damage in axons and neurodegeneration. [PMID:36917977] Neel DV, Basu H, Gunner G, Bergstresser Neuron 2023 0
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] Yu CH, Davidson S, Harapas CR, Hilton JB Cell 2020 0
Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced m [PMID:29400714] Shi Y, Lin S, Staats KA, Li Y, Chang WH, Nature medicine 2018 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning BIOMARKER in their description or question text

Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Anta

Score: 0.735 · Alzheimer's disease · 2026-04-04

## Mechanistic Overview Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Antagonist in Tau Ph

TDP-43 condensation thermodynamics as a therapeutic target and biomarker for nuc

Score: 0.724 · neuroscience · 2026-04-26

FRAP-based measurement of TDP-43 liquid-liquid phase separation state provides a continuous biomarker of nuclear-cytopla

Creatine Kinase System Capacity as Neural Energy Reserve Biomarker

Score: 0.707 · translational neuroscience · 2026-04-16

## Mechanistic Overview Creatine Kinase System Capacity as Neural Energy Reserve Biomarker starts from the claim that mo

CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic

Score: 0.705 · unknown disease · 2026-04-26

Aquaporin-4 (AQP4) water channels are normally concentrated at astrocyte end-feet ensheathing cerebral microvessels. Ear

Pericyte-targeted senolysis or senomorphic therapy will benefit only an early bi

Score: 0.700 · neurodegeneration · 2026-04-25

Therapeutic benefit from pericyte-directed senescence interventions depends on stage. If BBB leak and dysfunction occur

Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification Biomarker

Score: 0.677 · translational neuroscience · 2026-04-16

## Mechanistic Overview Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification Biomarker starts from the claim tha

Pericyte-First Sequential Biomarker Cascade — Soluble PDGFR-β as Sentinel Event

Score: 0.662 · unknown disease · 2026-04-26

CSF soluble PDGFR-β shedding from pericytes as the earliest detectable molecular event in AD, preceding amyloid/tau path

Retromer-dependent retrograde endosomal signaling compartmentalization as biomar

Score: 0.645 · neuroscience · 2026-04-26

VPS26/VPS29/VPS35 retromer complex maintains axonal endosomal signaling microdomains controlling TrkB/p75NTR trafficking

TREM2-Driven Senescence Biomarker Index for Predicting Neurodegeneration Risk

Score: 0.642 · neurodegeneration · 2026-04-20

**Molecular Mechanism and Rationale** The TREM2 (Triggering Receptor Expressed on Myeloid cells 2) pathway represents a

APOE ε4-driven microglial lipid handling as proximal driver in Non-Neuronal Tran

Score: 0.626 · neurodegeneration · 2026-04-28

APOE ε4-driven microglial lipid handling should produce a measurable proximal phenotype before late disease pathology. T

CSF Biomarker-Guided ABCA7 Therapeutic Dosing

Score: 0.619 · neurodegeneration · 2026-04-14

## **Molecular Mechanism and Rationale** ABCA7 (ATP-binding cassette transporter A7) functions as a critical lipid effl

Cell-state stratification is required to resolve Non-Neuronal Transcriptional Ch

Score: 0.612 · neurodegeneration · 2026-04-28

The question is likely underpowered or misleading unless analyses preserve the key strata: RNA-, APOE. Averaging across

Perturbation-first validation should precede therapeutic claims for Non-Neuronal

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Neurovascular Permeability Score (NVPS): Composite Plasma + Imaging Biomarker Pa

Score: 0.600 · unknown disease · 2026-04-26

A LASSO-optimized composite score integrating plasma GFAP, S100B, NFL, soluble PDGFR-β, and claudin-5 fragments to achie

GFAP Perivascular Redistribution (End-Feet Retraction) as True BBB Dysfunction B

Score: 0.594 · unknown disease · 2026-04-26

Spatial redistribution of GFAP from astrocyte end-feet to soma — not upregulation — is the mechanistically relevant BBB-